Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19
Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19
NCT ID: NCT04701502 Phase: PHASE2 Status: COMPLETED Enrollment: 60 Completion: 2021-02-15
Conditions
Covid19, Respiratory Disease, Immune System, Immunomodulator, Antiseptic, Supportive Care
Interventions
Viusid, Asbrip, Standard Care
Summary
This is a two-arm, randomized, open label, two-center, controlled study to evaluate the safety and efficacy of Viusid plus Asbrip in patients with mild and moderate symptoms of respiratory illness caused by Coronavirus 2019 infection.
Primary Outcome
Clinical Improvement